Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$113.87 USD

113.87
314,806

-0.68 (-0.59%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $113.78 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680

by Zacks Equity Research

Alkermes' (ALKS) phase II Vibrance-2 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with narcolepsy type 2.

Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth

by Zacks Equity Research

Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity. Stiff competition in the target market is a woe.

AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

JAZZ or CTLT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

JAZZ vs. CTLT: Which Stock Is the Better Value Option?

Wall Street Analysts Believe Jazz (JAZZ) Could Rally 56.66%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 56.7% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Is Jazz Pharmaceuticals (JAZZ) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.

Investing in Jazz (JAZZ)? Don't Miss Assessing Its International Revenue Trends

by Zacks Equity Research

Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View

by Zacks Equity Research

Jazz's (JAZZ) reports better-than-expected second quarter results. While it revises its guidance for 2024, it withdraws the financial guidance issued as part of the Vision 2025 plan.

Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of 13.25% and 2.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is The Options Market Predicting A Spike In JAZZ Pharmaceuticals (JAZZ) Stock?

by Zacks Equity Research

Investors need to pay close attention to JAZZ Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.

Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates

by Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.

JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals

by Zacks Equity Research

JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.

Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.

Jazz (JAZZ) International Revenue Performance Explored

by Zacks Equity Research

Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research

Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.

Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

by Zacks Equity Research

Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.